GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amniotics AB (OSTO:AMNI) » Definitions » Debt-to-EBITDA

Amniotics AB (OSTO:AMNI) Debt-to-EBITDA : 0.00 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Amniotics AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amniotics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was kr0.00 Mil. Amniotics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was kr0.00 Mil. Amniotics AB's annualized EBITDA for the quarter that ended in Sep. 2023 was kr-22.22 Mil. Amniotics AB's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Amniotics AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:AMNI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.74   Med: -0.05   Max: -0.01
Current: -0.74

During the past 4 years, the highest Debt-to-EBITDA Ratio of Amniotics AB was -0.01. The lowest was -0.74. And the median was -0.05.

OSTO:AMNI's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs OSTO:AMNI: -0.74

Amniotics AB Debt-to-EBITDA Historical Data

The historical data trend for Amniotics AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amniotics AB Debt-to-EBITDA Chart

Amniotics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
- -0.05 -0.01 -0.34

Amniotics AB Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.43 - -

Competitive Comparison of Amniotics AB's Debt-to-EBITDA

For the Biotechnology subindustry, Amniotics AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amniotics AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amniotics AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Amniotics AB's Debt-to-EBITDA falls into.



Amniotics AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Amniotics AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(15.067 + 0) / -44.864
=-0.34

Amniotics AB's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -22.216
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Amniotics AB  (OSTO:AMNI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Amniotics AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Amniotics AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Amniotics AB (OSTO:AMNI) Business Description

Traded in Other Exchanges
Address
Scheelevagen 2, Lund, SWE, 223 63
Amniotics AB is a biopharma company focusing on mesenchymal stem cells from amniotic fluid. It provides a novel platform for the production of medically superior mesenchymal stem cells including ethical and medically sound bio-banking opportunities for the newborn.

Amniotics AB (OSTO:AMNI) Headlines

From GuruFocus

American Noble Gas Announces Ticker Symbol Change

By Stock market mentor Stock market mentor 01-23-2023